Summit Therapeutics (SMMT) Common Equity: 2016-2025
Historic Common Equity for Summit Therapeutics (SMMT) over the last 10 years, with Sep 2025 value amounting to $192.3 million.
- Summit Therapeutics' Common Equity fell 56.10% to $192.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.3 million, marking a year-over-year decrease of 56.10%. This contributed to the annual value of $388.7 million for FY2024, which is 400.37% up from last year.
- According to the latest figures from Q3 2025, Summit Therapeutics' Common Equity is $192.3 million, which was down 25.89% from $259.4 million recorded in Q2 2025.
- Summit Therapeutics' 5-year Common Equity high stood at $437.9 million for Q3 2024, and its period low was $44.2 million during Q1 2024.
- Its 3-year average for Common Equity is $208.4 million, with a median of $192.3 million in 2025.
- In the last 5 years, Summit Therapeutics' Common Equity tumbled by 66.88% in 2024 and then soared by 678.85% in 2025.
- Over the past 5 years, Summit Therapeutics' Common Equity (Quarterly) stood at $83.3 million in 2021, then surged by 52.07% to $126.7 million in 2022, then tumbled by 38.66% to $77.7 million in 2023, then soared by 400.37% to $388.7 million in 2024, then plummeted by 56.10% to $192.3 million in 2025.
- Its Common Equity stands at $192.3 million for Q3 2025, versus $259.4 million for Q2 2025 and $344.3 million for Q1 2025.